Skip to main content
AmigoFish

Peptides and Cancer | 20+ Studies the Critics Won't Show You

From The Hunter Williams Podcast · · 30 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

All links here: ⁠https://hunterwilliamshealth.com/links

Timestamps:

00:00 Intro

01:00 Why I'm making this video

04:00 The plan: peptides with direct anti-cancer evidence

06:02 AOD-9604 and HGH Frag 176-191

07:42 BPC-157

09:54 DSIP (Delta Sleep Inducing Peptide)

11:08 Epitalon

12:30 Follistatin 344

13:30 GHK-Cu

14:36 Kisspeptin

15:58 KPV

17:18 LL-37

18:46 Melanotan 2

19:58 MOTS-c

21:12 Retatrutide

22:34 Semaglutide

23:40 SS-31

24:38 Thymalin

25:26 Thymosin Alpha-1

27:00 Tirzepatide

27:30 VIP (Vasoactive Intestinal Peptide)

28:06 Bottom line and closing thoughts

Description

If you spend any time in the peptide social media world, you've heard it. "Peptides cause cancer." It's the easiest way to scare someone off something, and a lot of people do it without ever showing you a single study.

So I went and pulled the studies. In this video I walk through every peptide on the popular research peptide list that actually has direct anti-cancer evidence in the published literature. Not theory. Not mechanism guesses. Actual studies in cells, animals, and in some cases, humans.

You'll see what the research says about BPC-157, GHK-Cu, Epitalon, KPV, LL-37, Thymosin Alpha-1, MOTS-c, semaglutide, tirzepatide, retatrutide, and a handful more. Some of this evidence is strong. Some is preliminary. I'm honest about both.

This is not medical advice and I'm not telling you peptides cure cancer. That's not what the data says and that's not what I'm claiming. What I am saying is that the next time someone hits you with a 60 second clip telling you peptides cause cancer, you'll have something more substantial to weigh it against.

All study links below.

📚 Studies Referenced (in order of appearance)

AOD-9604 / HGH Frag 176-191https://pmc.ncbi.nlm.nih.gov/articles/PMC9249349/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9249349/

BPC-157https://journals.lww.com/melanomaresearch/citation/2004/08000/bpc_157_inhibits_cell_growth_and_vegf_signalling.50.aspxhttps://pubmed.ncbi.nlm.nih.gov/29886825/

DSIP

https://pubmed.ncbi.nlm.nih.gov/12782416/

Epitalonhttps://pubmed.ncbi.nlm.nih.gov/14501183/

https://pubmed.ncbi.nlm.nih.gov/14501183/https://pubmed.ncbi.nlm.nih.gov/12209581/https://pubmed.ncbi.nlm.nih.gov/12049808/

Follistatin 344https://pmc.ncbi.nlm.nih.gov/articles/PMC9633376/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9633376/

GHK-Cuhttps://neoplasiaresearch.com/index.php/jao/article/view/217

https://neoplasiaresearch.com/index.php/jao/article/view/217https://www.lidsen.com/journals/genetics/genetics-05-02-128

Kisspeptinhttps://pubmed.ncbi.nlm.nih.gov/8944003/

https://pubmed.ncbi.nlm.nih.gov/8944003/https://pubmed.ncbi.nlm.nih.gov/28944853/

KPVhttps://pmc.ncbi.nlm.nih.gov/articles/PMC4957955/

https://pmc.ncbi.nlm.nih.gov/articles/PMC4957955/

LL-37https://pmc.ncbi.nlm.nih.gov/articles/PMC3910284/

https://pmc.ncbi.nlm.nih.gov/articles/PMC3910284/https://pmc.ncbi.nlm.nih.gov/articles/PMC3659029/

Melanotan 2https://pmc.ncbi.nlm.nih.gov/articles/PMC7013727/

https://pmc.ncbi.nlm.nih.gov/articles/PMC7013727/

MOTS-chttps://pmc.ncbi.nlm.nih.gov/articles/PMC11578304/

https://pmc.ncbi.nlm.nih.gov/articles/PMC11578304/

Retatrutidehttps://pmc.ncbi.nlm.nih.gov/articles/PMC11908972/

https://pmc.ncbi.nlm.nih.gov/articles/PMC11908972/

Semaglutidehttps://pmc.ncbi.nlm.nih.gov/articles/PMC11227080/

https://pmc.ncbi.nlm.nih.gov/articles/PMC11227080/https://pubmed.ncbi.nlm.nih.gov/38683947/https://pmc.ncbi.nlm.nih.gov/articles/PMC12587238/

SS-31https://pmc.ncbi.nlm.nih.gov/articles/PMC7923037/

https://pmc.ncbi.nlm.nih.gov/articles/PMC7923037/

Thymalinhttps://pubmed.ncbi.nlm.nih.gov/6752596/

https://pubmed.ncbi.nlm.nih.gov/6752596/https://pubmed.ncbi.nlm.nih.gov/29797130/

Thymosin Alpha-1https://pubmed.ncbi.nlm.nih.gov/8652276/…

Back to The Hunter Williams Podcast · Report a problem